Advisory Research Inc Cue Biopharma, Inc. Transaction History
Advisory Research Inc
- $548 Million
- Q4 2024
A detailed history of Advisory Research Inc transactions in Cue Biopharma, Inc. stock. As of the latest transaction made, Advisory Research Inc holds 257,225 shares of CUE stock, worth $264,941. This represents 0.05% of its overall portfolio holdings.
Number of Shares
257,225
Previous 257,225
-0.0%
Holding current value
$264,941
Previous $195,000
35.38%
% of portfolio
0.05%
Previous 0.04%
Shares
2 transactions
Others Institutions Holding CUE
# of Institutions
57Shares Held
11.9MCall Options Held
22KPut Options Held
1.2K-
Bleichroeder LP New York, NY5MShares$5.15 Million1.59% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.06MShares$2.12 Million0.0% of portfolio
-
Black Rock Inc. New York, NY757KShares$779,4380.0% of portfolio
-
Geode Capital Management, LLC Boston, MA631KShares$650,2190.0% of portfolio
-
Robertson Stephens Wealth Management, LLC San Francisco, CA479KShares$492,8550.02% of portfolio
About Cue Biopharma, Inc.
- Ticker CUE
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 35,381,700
- Market Cap $36.4M
- Description
- Cue Biopharma, Inc., a clinical-stage biopharmaceutical company, develops biologic drugs for the selective modulation of the human immune system to treat a range of cancers, chronic infectious diseases, and autoimmune disorders. Its lead drug candidate is CUE-101, a fusion protein biologic that is in Phase 1b clinical trial designed to target an...